
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KRAS CRISPR/Cas9 KO Plasmid (h) | sc-416674 | 20 µg | $397.00 | |||
KRAS HDR Plasmid (h) | sc-416674-HDR | 20 µg | $445.00 |
KRAS encodes a small GTPase that cycles between GDP- and GTP-bound states to relay signals from activated receptor tyrosine kinases to downstream effectors. As a central node in the RAS–RAF–MEK–ERK (MAPK) cascade and PI3K–AKT signaling, KRAS regulates proliferation, differentiation, metabolism, and survival, with crosstalk into cytoskeletal remodeling and vesicular trafficking programs. Dysregulated KRAS signaling perturbs feedback control and rewires transcriptional and metabolic outputs, contributing to oncogenic transformation and altered cellular stress responses. Human KRAS is therefore widely studied in pathway mapping, genotype–phenotype relationships, and mechanistic models of signal transduction.
KRAS CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KRAS gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the KRAS locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, KRAS HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined KRAS target site.
When co-transfected with KRAS CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the KRAS locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.